EUVIMEDEUVIMED entdecken
Crossref

Repurposing of FDA Approved Drugs and Neuropep peptides as Anticancer Agents Against ErbB1 and ErbB2

Sunil Kumar Patnaik, Akey Krishna Swaroop, Mudavath Ravi Naik, Jubie Selvaraj, Moola Joghee Nanjan Chandrasekar iD

Drug Research · 01.07.2023 · 73 (06) · 341-348

DOI: 10.1055/a-2030-4078 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Research, erschienen am 01.07.2023. Verfasst von Sunil Kumar Patnaik und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, The Nilgiris, Tamilnadu, India. Hauptthemen laut MEDLINE: Drug Repositioning, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ErbB1 and ErbB2 are the most important biological targets in cancer drug discovery and development of dual inhibitors for the cancer therapy. FDA approved drugs and Neuropep peptides were used to fit into the ATP binding site of the tyrosine kinases; ErbB1 and ErbB2 proteins. Cytoscape, iGEMDOCK, HPEPDOCK and DataWarrior softwares were used to study the role of these agents as anticancer drugs. Eleven FDA approved drugs and eleven Neuropep peptides showed the strongest 2D interactions and significant binding energy with the proteins. Invitro MTT anticancer assay revealed that, the test compounds, peptide YSFGL and doxorubicin showed significant IC50 value (µM) of 26.417±0.660 and 7.675±0.278 respectively which are compared with the lapatinib standard IC50 value (µM) of 2.380±0.357 against A549 cells and IC50 value (µM) of 39.047±0.770 and 8.313±0.435 respectively which are compared with the lapatinib standard IC50 value (µM) of 3.026±0.180 against MDA-MB-231 cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug RepositioningAntineoplastic AgentsLapatinibQuinazolinesPeptides

Substanzen

LapatinibQuinazolinesAntineoplastic AgentsPeptides

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, The Nilgiris, Tamilnadu, India.
  • Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, The Nilgiris, Tamilnadu, India.
  • School of Life Sciences, JSS Academy of Higher Education & Research(Ooty Campus), Longwood, Mysuru Road, Ooty-643001, Tamilnadu, India.

ORCID-Profile: Moola Joghee Nanjan Chandrasekar

Zitieren

APA

Patnaik, S. K., Swaroop, A. K., Naik, M. R., Selvaraj, J., & Chandrasekar, M. J. N. (2023). Repurposing of FDA Approved Drugs and Neuropep peptides as Anticancer Agents Against ErbB1 and ErbB2. Drug Research, 73(06), 341-348. https://doi.org/10.1055/a-2030-4078

Vancouver

Patnaik SK, Swaroop AK, Naik MR, Selvaraj J, Chandrasekar MJN. Repurposing of FDA Approved Drugs and Neuropep peptides as Anticancer Agents Against ErbB1 and ErbB2. Drug Research. 2023;73(06):341-348. doi:10.1055/a-2030-4078

BibTeX
@article{Patnaik2023,
  author = {Patnaik, Sunil Kumar and Swaroop, Akey Krishna and Naik, Mudavath Ravi and Selvaraj, Jubie and Chandrasekar, Moola Joghee Nanjan},
  title = {Repurposing of FDA Approved Drugs and Neuropep peptides as Anticancer Agents Against ErbB1 and ErbB2},
  journal = {Drug Research},
  year = {2023},
  volume = {73},
  number = {06},
  pages = {341--348},
  doi = {10.1055/a-2030-4078}
}
Kostenlos starten →